Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through. Fair value range: low $225, high $370, with mid-point at $297.
Engelse bron wordt weergegeven terwijl we vertalen
Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.
§1 Samenvatting
Stryker benefits from high switching costs and Mako ecosystem lock-in.
Fair value mid-point of $297.38 implies only 1% upside, prompting a Hold.
Trades at a massive premium to peers (PEG 2.51), posing severe multiple contraction risk if growth slows.
Watch Mako placement volumes and 20.5% operating margin stability.
Fair value
$297
Margin of safety
+1.0%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$294.45Price
Low $225.47
Mid $297.38
High $370.47
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.
High switching costs in hospital
High switching costs in hospital ecosystems
Scale economies in MedSurg and
Scale economies in MedSurg and Orthopaedics
Cycle upside
Accelerating hospital capital expenditures and aging demographics driving elective procedure volumes.
Each scenario for SYK (SYK) carries a five-year price target, an explicit set of assumptions (growth, terminal multiple, margin path), and a probability weight calibrated against current visibility.
Probability weights start from a 25/50/25 default and are asymmetry-adjusted: when downside risk is elevated, base + bear gain weight; when visibility is high (long RPO, multi-year contracts), bull and base both gain.
Expected return is the probability-weighted average of the three scenario returns. The expected-value table reports the weighted price, weighted return, and asymmetry to help the reader compare risk-reward against the rating band.
When our composite fair value differs from private calibration references by more than 30%, the calibration-divergence diagnostic is run to identify which assumptions drive the gap; the result is summarised in the parent valuation surface.
FAQ
SYK — frequently asked questions
Based on our latest analysis, SYK trades close to fair value. The current price is $294 versus a composite fair-value midpoint of $297 (range $225–$370), which implies roughly 1.0% upside to the midpoint.
Our composite fair-value range for SYK is $225–$370, with a midpoint of $297. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for SYK's archetype.
Our current rating for SYK is Hold with a confidence score of 88/100. Hold. Current price ($294.45) is near our composite mid-point ($297.38) with balanced upside/downside risk. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for SYK are: Multiple Contraction to Peer Median; Orthopaedic Pricing Collapse; Robotics CapEx Freeze. The single biggest risk is Multiple Contraction to Peer Median: SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.
Our current rating for SYK is Hold, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($225–$370) versus the current price of $294.
SYK is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for SYK.
